Emerging novel therapies in the treatment of castrate-resistant prostate cancer

Authors

  • Alym Abdulla McMaster Institute of Urology, Division of Urology, Department of Surgery McMaster University, Hamilton, ON
  • Anil Kapoor McMaster Institute of Urology, Division of Urology, Department of Surgery McMaster University, Hamilton, ON

DOI:

https://doi.org/10.5489/cuaj.609

Abstract

The treatment options for patients with castration-resistant prostate
cancer (CRPC), until very recently, only included docetaxel.
In the past 10 months, newly Federal Drug Administration (FDA)
approved agents in the United States have shown survival benefit
for patients with CRPC. This review takes a closer look at
these newer agents: sipuleucel-T (immune therapy) and cabazitaxel
(cytotoxic therapy). We also review the evidence supporting
the FDA’s approval of denosumab (bone-targeted therapy)
as a treatment option for men with CRPC and bony metastases.
Newer agents currently being investigated in phase III clinical trials
for their potential role in metastatic CRPC are also reviewed.
These agents include abiraterone (hormonal therapy), TAK-700
(hormonal therapy), MDV3100 (hormonal therapy), ipilimumab
(immune therapy), zibotentan (endothelin-A receptor antagonist)
and dasatinib (tyrosine kinase inhibitor). As ongoing studies using
all the aforementioned agents continue to evolve, our understanding
of how and where these agents fit into the treatment paradigm
for patients with CRPC will become clearer.

Downloads

Download data is not yet available.

Author Biographies

Alym Abdulla, McMaster Institute of Urology, Division of Urology, Department of Surgery McMaster University, Hamilton, ON

Anil Kapoor, McMaster Institute of Urology, Division of Urology, Department of Surgery McMaster University, Hamilton, ON

Downloads

How to Cite

Abdulla, A., & Kapoor, A. (2013). Emerging novel therapies in the treatment of castrate-resistant prostate cancer. Canadian Urological Association Journal, 5(2), 120–33. https://doi.org/10.5489/cuaj.609

Issue

Vol. 5 No. 2 (2011): April

Section

Review

License

You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:

  • Post the Article on any Web site
  • Translate or authorize a translation of the Article
  • Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
  • Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.

The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.

You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.

The CUA also requires you to warrant the following:

  • That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
  • That all individuals who have made a substantive contribution to the article are acknowledged;
  • That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
  • That the Article does not libel or violate the privacy rights of any third party.